Santen Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Santen Pharmaceutical's earnings have been declining at an average annual rate of -37.6%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 4.1% per year.
Key information
-37.6%
Earnings growth rate
-37.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 4.1% |
| Return on equity | -5.1% |
| Net Margin | -5.4% |
| Next Earnings Update | 03 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Santen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 279,037 | -14,955 | 96,257 | 28,297 |
| 31 Dec 22 | 270,242 | -8,195 | 125,789 | 2,879 |
| 30 Sep 22 | 266,413 | -9,133 | 123,254 | 1,929 |
| 30 Jun 22 | 266,804 | 26,533 | 119,590 | 979 |
| 31 Mar 22 | 266,257 | 27,212 | 120,610 | 0 |
| 31 Dec 21 | 263,620 | 5,056 | 121,088 | 1,150 |
| 30 Sep 21 | 259,459 | 7,319 | 119,996 | 1,215 |
| 30 Jun 21 | 257,028 | 7,978 | 118,482 | 504 |
| 31 Mar 21 | 249,605 | 6,826 | 113,586 | 0 |
| 31 Dec 20 | 241,015 | 24,430 | 106,585 | 500 |
| 30 Sep 20 | 241,685 | 24,279 | 106,419 | -289 |
| 30 Jun 20 | 239,982 | 23,404 | 106,103 | -558 |
| 31 Mar 20 | 241,555 | 23,616 | 106,599 | 0 |
| 31 Dec 19 | 243,142 | 28,876 | 103,631 | 62 |
| 30 Sep 19 | 238,457 | 30,721 | 101,968 | 448 |
| 30 Jun 19 | 236,679 | 31,498 | 101,894 | 555 |
| 31 Mar 19 | 234,026 | 31,953 | 102,020 | 0 |
| 31 Dec 18 | 229,560 | 31,291 | 101,646 | -804 |
| 30 Sep 18 | 228,512 | 34,370 | 101,724 | -778 |
| 30 Jun 18 | 225,477 | 33,083 | 101,043 | 6 |
| 31 Mar 18 | 224,942 | 35,247 | 99,926 | 0 |
| 31 Dec 17 | 217,021 | 30,580 | 65,855 | 24,751 |
| 30 Sep 17 | 212,041 | 25,717 | 63,872 | 24,224 |
| 30 Jun 17 | 205,038 | 24,756 | 61,890 | 23,241 |
| 31 Mar 17 | 199,096 | 23,061 | 60,934 | 22,786 |
| 31 Dec 16 | 196,754 | 23,299 | 59,898 | 21,636 |
| 30 Sep 16 | 195,247 | 22,317 | 59,532 | 21,051 |
| 30 Jun 16 | 197,322 | 53,155 | 59,169 | 20,561 |
| 31 Mar 16 | 195,291 | 53,373 | 58,382 | 19,990 |
| 31 Dec 15 | 194,193 | 57,729 | 40,107 | 31,761 |
| 30 Sep 15 | 187,779 | 58,590 | 43,524 | 26,720 |
| 30 Jun 15 | 176,124 | 27,842 | 46,681 | 22,064 |
| 31 Mar 15 | 161,831 | 24,032 | 48,074 | 17,477 |
| 31 Dec 14 | 156,559 | 17,923 | 52,398 | 19,040 |
| 30 Sep 14 | 151,325 | 17,214 | 48,597 | 19,040 |
| 30 Jun 14 | 148,031 | 15,278 | 45,812 | 19,040 |
| 31 Mar 14 | 148,663 | 17,109 | 44,104 | 19,040 |
| 31 Dec 13 | 139,587 | 17,760 | 40,808 | 16,719 |
| 30 Sep 13 | 131,614 | 16,536 | 38,997 | 16,719 |
| 30 Jun 13 | 125,422 | 17,805 | 36,775 | 16,719 |
| 31 Mar 13 | 119,066 | 16,520 | 36,164 | 16,719 |
| 31 Dec 12 | 116,403 | 16,530 | 35,902 | 17,225 |
| 30 Sep 12 | 114,342 | 16,233 | 35,434 | 17,225 |
| 30 Jun 12 | 114,524 | 15,911 | 36,025 | 17,225 |
Quality Earnings: 4536 N is currently unprofitable.
Growing Profit Margin: 4536 N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4536 N is unprofitable, and losses have increased over the past 5 years at a rate of 37.6% per year.
Accelerating Growth: Unable to compare 4536 N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4536 N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.1%).
Return on Equity
High ROE: 4536 N has a negative Return on Equity (-5.11%), as it is currently unprofitable.